CYTK — CYTOKINETICS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1061983 ·
Last close
$68.45
Market Cap
$9.29B
52W High
$80.20
52W Low
$58.43
ADV30
3,070,002
Next earnings
2026-05-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 19,355,000 | 16,803,000 | -183,618,000 | -206,031,000 | 1,273,478,000 | 129,843,000 | 2,100,046,000 |
| Dec 2025 | 17,755,000 | -86,643,000 | -178,366,000 | -183,031,000 | 1,424,537,000 | 122,518,000 | 2,084,162,000 |
| Sep 2025 | 1,936,000 | -97,297,000 | -166,755,000 | -306,178,000 | 1,436,557,000 | 225,467,000 | 1,957,680,000 |
| Jun 2025 | 66,769,000 | -45,785,000 | -111,506,000 | -134,370,000 | 1,225,635,000 | 74,940,000 | 1,594,355,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-523,849,000
Investing CF
$56,202,000
Financing CF
$527,474,000
CapEx
$-25,073,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.84
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-3,692,750,000
Inventory
$154,000
Receivables
$6,827,000
ST Investments
$688,707,000
EBIT TTM
$-715,353,000
Pretax Income TTM
$-829,610,000
Interest Exp TTM
$114,257,000
Analysts
19
Yahoo Snapshot (yfinance, live)
Total Revenue
$105,815,000
EBITDA
$-629,041,984
Free Cash Flow
$-381,057,760
Enterprise Value
$9,074,043,904
Total Cash
$818,550,016
Total Debt
$1,443,623,040
Shares Out
135,770,593
Trailing EPS
$-6.85
Book Value
$-6.65
ROE
—
ROA
-31.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 88,039,000 | -612,258,000 | -784,955,000 | 1,424,537,000 | 2,084,162,000 | — | -510,009,000 |
| Dec 2024 | 18,474,000 | -536,248,000 | -589,526,000 | 1,401,673,000 | 1,537,045,000 | — | -395,890,000 |
| Dec 2023 | 7,530,000 | -496,205,000 | -526,244,000 | 824,316,000 | 1,210,639,000 | — | -414,333,000 |
| Dec 2022 | 94,588,000 | -324,202,000 | -388,955,000 | 1,014,775,000 | 1,122,675,000 | — | -299,516,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.75
Max Pain — expiry 2026-06-18
max pain strike: $55.00 · spot: $68.45 · call oi: 23 · put oi: 5,960
Expected Move to 2026-06-18:
±$6.20
(9.06%) —
implied range
$62.25 –
$74.65
· ATM straddle on $70.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NUVL | Nuvalent, Inc. | $9.07B | $123.25 | — |
| ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $10.33B | $73.33 | — |
| CORT | CORCEPT THERAPEUTICS INC | $8.32B | $77.49 | — |
| ABVX | Abivax S.A. | $8.19B | $102.72 | — |
| AAVXF | Abivax S.A. | $8.07B | $101.25 | — |
News headlines (Yahoo Finance, 1h cache)
Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program
2026-06-08 11:30 · Yahoo
First MYQORZO Launch In Germany Might Change The Case For Investing In Cytokinetics (CYTK)
2026-06-08 10:07 · Yahoo
Why Is Cytokinetics (CYTK) Down 5.5% Since Last Earnings Report?
2026-06-04 15:30 · Yahoo
Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany
2026-06-01 11:30 · Yahoo
Citi Calls Cytokinetics, Incorporated (CYTK) a “Top Pick” Among Small-to-Mid Cap Biotech Stocks
2026-05-28 10:59 · Yahoo
Cytokinetics to Participate in June Investor Conferences
2026-05-27 20:00 · Yahoo
A Look At Cytokinetics (CYTK) Valuation After A Strong Multi‑Year Share Price Performance
2026-05-25 21:15 · Yahoo
Citi Names 2 Biotech Stocks ‘Top Picks’ for 2026
2026-05-24 17:58 · Yahoo
Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise
2026-05-22 20:04 · Yahoo
Cytokinetics to Hold Annual Meeting of Stockholders
2026-05-20 20:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.